Cargando…
Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China
Aim. Our aim is to survey the treatment effect of PEG-IFN plus ribavirin in patients infected with HCV genotype 6a in Guangdong and Guangxi province of China and investigate best course of antiviral treatment for patients with HCV-6a infection. Methods. 515 eligible patients received subcutaneous 18...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789432/ https://www.ncbi.nlm.nih.gov/pubmed/27034655 http://dx.doi.org/10.1155/2016/5397407 |
_version_ | 1782420856327110656 |
---|---|
author | Tong, Wangxia Zhu, Jianyun Luo, Ning Yang, Xiaohua Lei, Zhiying Huang, Xiaoliang Zhao, Zhixin Zhang, Xiaohong Gao, Zhiliang Jiang, Zhonghua |
author_facet | Tong, Wangxia Zhu, Jianyun Luo, Ning Yang, Xiaohua Lei, Zhiying Huang, Xiaoliang Zhao, Zhixin Zhang, Xiaohong Gao, Zhiliang Jiang, Zhonghua |
author_sort | Tong, Wangxia |
collection | PubMed |
description | Aim. Our aim is to survey the treatment effect of PEG-IFN plus ribavirin in patients infected with HCV genotype 6a in Guangdong and Guangxi province of China and investigate best course of antiviral treatment for patients with HCV-6a infection. Methods. 515 eligible patients received subcutaneous 180 μg PEG-IFNα-2a or 1.5 μg/kg PEG-IFNα-2b once weekly plus oral ribavirin. Primary outcome was SVR by intention-to-treat analysis. Secondary outcome was RVR, cEVR, ETR, and relapse rate. Results. SVR in patients with HCV-6a infection treated for 48 weeks was comparable to that in patients with HCV-2/3 infection (80.9% versus 82.5%, p = 0.812) and higher than that in patients with HCV-1b infection (80.9% versus 67.2%, p = 0.014). ETR (98.9% versus 90.6%, p = 0.016), virological response at month 3 of end-of- treatment (88.8% versus 76.6%, p = 0.044), SVR (80.9% versus 65.6%, p = 0.032), and virological response at month 12 of end-of-treatment (76.4% versus 60.9%, p = 0.04) in patients with HCV-6a infection treated for 48 weeks were higher than those in patients with HCV-6a infection treated for 24 weeks. Conclusion. SVR in patients with HCV-6a treated for 48 weeks was comparable to that in patients with HCV-2/3 infection and higher than that in patients with HCV-1b infection; patients with HCV-6a infection treated for 48 weeks had a superior treatment response than patients treated for 24 weeks. |
format | Online Article Text |
id | pubmed-4789432 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-47894322016-03-31 Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China Tong, Wangxia Zhu, Jianyun Luo, Ning Yang, Xiaohua Lei, Zhiying Huang, Xiaoliang Zhao, Zhixin Zhang, Xiaohong Gao, Zhiliang Jiang, Zhonghua Gastroenterol Res Pract Research Article Aim. Our aim is to survey the treatment effect of PEG-IFN plus ribavirin in patients infected with HCV genotype 6a in Guangdong and Guangxi province of China and investigate best course of antiviral treatment for patients with HCV-6a infection. Methods. 515 eligible patients received subcutaneous 180 μg PEG-IFNα-2a or 1.5 μg/kg PEG-IFNα-2b once weekly plus oral ribavirin. Primary outcome was SVR by intention-to-treat analysis. Secondary outcome was RVR, cEVR, ETR, and relapse rate. Results. SVR in patients with HCV-6a infection treated for 48 weeks was comparable to that in patients with HCV-2/3 infection (80.9% versus 82.5%, p = 0.812) and higher than that in patients with HCV-1b infection (80.9% versus 67.2%, p = 0.014). ETR (98.9% versus 90.6%, p = 0.016), virological response at month 3 of end-of- treatment (88.8% versus 76.6%, p = 0.044), SVR (80.9% versus 65.6%, p = 0.032), and virological response at month 12 of end-of-treatment (76.4% versus 60.9%, p = 0.04) in patients with HCV-6a infection treated for 48 weeks were higher than those in patients with HCV-6a infection treated for 24 weeks. Conclusion. SVR in patients with HCV-6a treated for 48 weeks was comparable to that in patients with HCV-2/3 infection and higher than that in patients with HCV-1b infection; patients with HCV-6a infection treated for 48 weeks had a superior treatment response than patients treated for 24 weeks. Hindawi Publishing Corporation 2016 2016-02-28 /pmc/articles/PMC4789432/ /pubmed/27034655 http://dx.doi.org/10.1155/2016/5397407 Text en Copyright © 2016 Wangxia Tong et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Tong, Wangxia Zhu, Jianyun Luo, Ning Yang, Xiaohua Lei, Zhiying Huang, Xiaoliang Zhao, Zhixin Zhang, Xiaohong Gao, Zhiliang Jiang, Zhonghua Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China |
title | Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China |
title_full | Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China |
title_fullStr | Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China |
title_full_unstemmed | Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China |
title_short | Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China |
title_sort | response to pegylated interferon plus ribavirin in patients with hepatitis c virus genotype 6a infection from guangdong and guangxi province of china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789432/ https://www.ncbi.nlm.nih.gov/pubmed/27034655 http://dx.doi.org/10.1155/2016/5397407 |
work_keys_str_mv | AT tongwangxia responsetopegylatedinterferonplusribavirininpatientswithhepatitiscvirusgenotype6ainfectionfromguangdongandguangxiprovinceofchina AT zhujianyun responsetopegylatedinterferonplusribavirininpatientswithhepatitiscvirusgenotype6ainfectionfromguangdongandguangxiprovinceofchina AT luoning responsetopegylatedinterferonplusribavirininpatientswithhepatitiscvirusgenotype6ainfectionfromguangdongandguangxiprovinceofchina AT yangxiaohua responsetopegylatedinterferonplusribavirininpatientswithhepatitiscvirusgenotype6ainfectionfromguangdongandguangxiprovinceofchina AT leizhiying responsetopegylatedinterferonplusribavirininpatientswithhepatitiscvirusgenotype6ainfectionfromguangdongandguangxiprovinceofchina AT huangxiaoliang responsetopegylatedinterferonplusribavirininpatientswithhepatitiscvirusgenotype6ainfectionfromguangdongandguangxiprovinceofchina AT zhaozhixin responsetopegylatedinterferonplusribavirininpatientswithhepatitiscvirusgenotype6ainfectionfromguangdongandguangxiprovinceofchina AT zhangxiaohong responsetopegylatedinterferonplusribavirininpatientswithhepatitiscvirusgenotype6ainfectionfromguangdongandguangxiprovinceofchina AT gaozhiliang responsetopegylatedinterferonplusribavirininpatientswithhepatitiscvirusgenotype6ainfectionfromguangdongandguangxiprovinceofchina AT jiangzhonghua responsetopegylatedinterferonplusribavirininpatientswithhepatitiscvirusgenotype6ainfectionfromguangdongandguangxiprovinceofchina |